Freelance reporter. Reach out privately on Signal: jaredwhitlock.73
San Diego
Joined September 2010
- Tweets2K
- Following865
- Followers1.6K
- Likes4.2K
Pinned Tweet
For families, a $2.1M medicine can feel like both a miracle and an out-of-reach reality.
Now, biotechs in China are racing to develop lower-cost alternatives:
endpoints.news/chinese-biote…
Jared Whitlock retweeted
A couple paid more than $800,000 for a gene-editing therapy for their daughter. She died, and it wasn’t made public. An exclusive by @bborrell from us and @ScienceMagazine.
science.org/content/article/…
Jared Whitlock retweeted
Remembering J. Craig Venter: a relentless scientist who changed biotech — and was all too easily misunderstood
statnews.com/2026/04/30/crai… via @statnews
Jared Whitlock retweeted
I'm sad to learn that J. Craig Venter, a key figure in modern genomics and an inveterate troublemaker, passed away.
Craig was very important to the study of human genetics and the biotechnology industry. He also had an impact on my career. The pitch that led @michaelnoer to hire me at Forbes in 2000 was about Venter's company, Celera Genomics, and its work on the mouse genome.
Seventeen years, later, Michael edited a cover story I wrote about Venter for Forbes.
Jared Whitlock retweeted
Must read story from @antonioregalado about a biotech that wants to make brainless clones as a personal source of organ donation or even body transplant. They pitched themselves to me as an alternative to animal models company. That wasn't the full story. technologyreview.com/2026/03…
Jared Whitlock retweeted
Theia Group set out to revolutionize space-based surveillance. Its enigmatic founder, a former NASA engineer, envisioned nothing less then "Google for the physical world," he told me from jail.
My @BW investigation into Theia's dramatic rise & fall:
bloomberg.com/news/features/…
ICYMI: Multimillion-dollar gene therapies weren’t supposed to face competition. China has other plans
Reporting here: endpoints.news/china-is-taki…
Jared Whitlock retweeted
China competition is coming for the US's multimillion-dollar gene therapies -- a must-read from @Jared_Whitlock about what's happening there and how it will affect access around the world:
endpoints.news/china-is-taki…
Multimillion-dollar gene therapies weren’t supposed to face competition. China has other plans
My latest feature for @endpts, complete with data analysis.
endpoints.news/china-is-taki…
Jared Whitlock retweeted
Did the FDA’s individualized therapy guidance put a spike in the heart of a startup biotech? Fake news, says the HHS. Yeah, it did, says an insider. Exclusive from @RLCscienceboss and @Jared_Whitlock
endpoints.news/everyone-medi…
Jared Whitlock retweeted
EveryOne Medicines shuts down, ending custom cure venture that banked on new FDA pathway
endpoints.news/everyone-medi…
Exclusive: EveryOne Medicines shuts down, ending custom cure venture that banked on new FDA pathway
From @RLCscienceboss and me:
endpoints.news/everyone-medi…
Jared Whitlock retweeted
Hey everyone! I'm starting a monthly newsletter on @Substack of curated longform journalism recommendations. I'll be highlighting the stories that've stuck with me the most each month + two books & a podcast. 1st post here. Please subscribe and share! open.substack.com/pub/thelon…
After rallying, Grail's cancer test faces new uncertainty due to UK study
My latest via @endpts:
endpoints.news/grails-cancer…
A Chinese biotech says its gene therapy slowed aggressive brain cancer in an early human test, but the debated approach is already drawing skepticism from some researchers.
My latest. @endpts
endpoints.news/neuexcell-the…
Jared Whitlock retweeted
Honored to have won a George Polk award for my coverage of the turmoil at FDA last year. The STAT team was also recognized for reporting on the Trump admin's impact on health and science. statnews.com/2026/02/18/stat…
Jared Whitlock retweeted
With a valuation of about $61 billion, Hengrui is now larger than Takeda and Bayer.
But there’s still one big item on its bucket list: selling its own treatments outside of China. My story in @endpts:
endpoints.news/hengrui-blaze…
Jared Whitlock retweeted
At #JPM26, pharma leaders said the US should focus on fixing its own biopharma system, not slowing China’s rise in drug development. endpoints.news/jpm26-drugmak…
Dispatch from #JPM2026:
Drugmakers and investors want US reforms, not to slow down China
endpoints.news/jpm26-drugmak…
Jared Whitlock retweeted
You know the China biotech story is here to stay when Endpoints starts hiring in Hong Kong. Exciting opportunity!
📢Some BIG news here at Endpoints: We're building in China. This year, we'll be hiring a senior journalist in Hong Kong who can lead on our coverage of China biotech.
This is one of biotech's most important stories. Want to shape it? DM me, or apply.
ats.rippling.com/endpointsne…